Overview of Actrapid Penfill

Property	Description
Active Ingredient	Human Insulin (Soluble/Neutral)
Form	Solution for injection (in a 3 mL Penfill cartridge)
Pharmacological Class	Anti-diabetic agent; Short-Acting Insulin
Common Use	Mealtime (Prandial) blood sugar control in diabetes mellitus
Manufacturer	Novo Nordisk A/S
Regulatory Status	Prescription Only Medicine (Rx)

What Type of Medicine is Actrapid Penfill?

Actrapid Penfill is a widely known brand name for a form of injectable, short-acting insulin used in the therapeutic management of diabetes mellitus. It contains the active ingredient human insulin, which is structurally identical to the hormone naturally produced by the pancreas. It is classified as a human insulin preparation used as a fast-acting agent, belonging to the therapeutic class of insulins and analogues. The Penfill presentation refers specifically to the 3 mL glass cartridge designed for use with compatible insulin delivery pen systems manufactured by Novo Nordisk.

What is the Origin and Composition of the Insulin?

The insulin found in Actrapid Penfill is a biosynthetic form of human insulin, meaning it is manufactured using recombinant DNA technology to ensure purity and consistency. This consistency in manufacturing is a key factor that has contributed to its broad clinical recognition for predictable action profiles. This method employs specialized non-pathogenic organisms, such as Saccharomyces cerevisiae (yeast), to reliably produce the human insulin. The final product is a clear, aqueous solution that includes stabilizing excipients like glycerol and metacresol to maintain product integrity within the cartridge.

What is the Primary Therapeutic Purpose?

The primary therapeutic purpose of Actrapid Penfill is to provide essential replacement insulin therapy, particularly for covering carbohydrate intake during meals. As a short-acting product, it is clinically recognized for its ability to quickly lower post-meal blood sugar spikes, a crucial component of effective blood glucose control in both Type 1 and Type 2 diabetes. It is typically prescribed as a prandial (mealtime) component of an insulin regimen, complementing the action of longer-acting insulins.

Regulatory References

What side effects are possible with Actrapid Penfill?

Possible Side Effects and Safety Information

Official regulatory documents categorize the safety profile of Actrapid Penfill, a human insulin product, primarily based on the outcomes of its blood glucose-lowering action and local administration effects. The most frequent safety consideration is directly related to the medicine's therapeutic effect.

Official Adverse Reaction Classification

Frequency Classification	Associated Adverse Reaction	System-Organ Class
Very Common (ge 1/10)	Hypoglycaemia (Low blood sugar)	Metabolism and Nutrition Disorders
Common (ge 1/100)	Injection site reactions (e.g., pain, redness, swelling)	Skin and Subcutaneous Tissue Disorders
Uncommon (ge 1/1,000)	Systemic Hypersensitivity (Generalized allergy); Lipodystrophy (Tissue changes at injection site); Edema (Swelling)	Immune System Disorders; Skin Disorders; General Disorders
Rare (ge 1/10,000)	Acute painful peripheral neuropathy	Nervous System Disorders

Serious Adverse Reactions

The label documents specific serious adverse events, including Severe Hypoglycaemia, which can lead to unconsciousness, and Systemic Hypersensitivity, a rare generalized allergic reaction that may involve bronchospasm or anaphylaxis. Additionally, all insulins are noted to carry the risk of Hypokalemia, a potentially dangerous drop in serum potassium levels.

Population and Time-Related Safety Considerations

The official labeling notes that effects like Edema and transient painful neuropathy may occur at the initiation of treatment or during rapid improvement in glucose control. For specific populations, regulatory documents specify that patients with renal or hepatic impairment and older adults require careful and frequent blood glucose monitoring due to potentially altered insulin clearance. Actrapid is restricted from use during episodes of active hypoglycemia or in cases of known hypersensitivity to human insulin or its excipients.

Overdose and Emergency Response

Actrapid Penfill overdose is strictly defined in regulatory documents as hypoglycaemia (low blood glucose), which occurs when the insulin dose administered is in excess of the physiological requirement. The officially recognized manifestations are classified into two progressive stages.

Documented Overdose Manifestations

Initial Manifestations: Mild hypoglycaemic episodes may present with specific neurovegetative and neurological signs, including cold sweats, rapid heartbeat, headache, tremor, feeling anxious, and difficulty in concentrating. These initial signs are officially addressed by the immediate intake of oral carbohydrate or glucose.
Severe Manifestations: Advanced overdose may lead to severe symptoms such as unconsciousness and convulsions. The regulatory text documents the risk of temporary or permanent impairment of brain function or death if not addressed.

Required Emergency Actions

For severe overdose leading to unconsciousness, the regulator-mandated emergency measure is the administration of Glucagon (0.5 to 1 mg IM or SC). Immediate medical help must be sought following any Glucagon administration, as the patient requires hospital monitoring to determine the cause and prevent relapse. Regulatory information also notes that patients with longstanding diabetes may experience a loss of initial warning signs, necessitating acute awareness of the severe manifestations.

Therapeutic Uses of Actrapid Penfill

What Actrapid Penfill Treats: Main Uses and Benefits

Actrapid Penfill is used to provide the essential, supplemental insulin needed to control high blood sugar in patients with diabetes mellitus. It is generally used across domains where additional symptomatic support is needed to correct metabolic imbalance.

Management of Blood Sugar Spikes After Meals

This short-acting insulin is commonly used to help manage postprandial hyperglycemia, which are the rapid rises in blood glucose levels that occur after consuming carbohydrates. Its application assists with maintaining functional stability by addressing these significant glucose excursions.

Relief of Systemic Hyperglycemic Symptoms

Actrapid is relevant for managing the symptom clusters that interfere with daily comfort and create noticeable physiological strain, such as excessive thirst, frequent urination, and profound fatigue. By supporting the correction of high glucose levels, it assists with maintaining functional stability, which helps patients cope more steadily with symptom fluctuations.

Stabilization in Acute Care and Stress Situations

Actrapid Penfill is applied in clinical settings that involve acute or unstable symptom patterns, specifically for treating severe conditions like Diabetic Ketoacidosis and the Hyperosmolar Non-ketotic Syndrome. It is also considered relevant when supportive symptom management is appropriate during periods of heightened physiological stress, such as major surgery or concurrent severe illness, and may contribute to reducing the likelihood of symptomatic complications.

Quick Fact: Relief for Postprandial Hyperglycemia The goal is managing acute and predictable blood sugar surges that follow meals, which supports day-to-day metabolic stability.

Regulatory References

European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Actrapid Penfill?

The population eligibility for Actrapid Penfill is strictly defined by regulatory documents, focusing on absolute prohibitions and conditional use for specific groups.

Contraindicated Populations

Actrapid Penfill is strictly contraindicated and must not be used in individuals who have a known hypersensitivity (allergy) to human insulin or any of its excipients. Furthermore, the medicine must never be injected during an episode of, or when there is suspicion of, hypoglycemia (low blood sugar), as this is an absolute contraindication.

Age- and Condition-Based Eligibility

Use is established for adults and pediatric patients (children and adolescents) aged 2 years and above. However, safety and efficacy have not been established in children younger than 2 years of age.

Use is permitted but requires careful monitoring and potential dose adjustment for older adults (aged 65 years and over), as well as patients with renal (kidney) or hepatic (liver) impairment. These conditions may alter the body's insulin requirements.

Pregnancy and Lactation Status

There are no restrictions on using Actrapid Penfill for the management of diabetes during pregnancy or lactation (breastfeeding). Insulin does not pass the placental barrier and presents no risk to the nursing infant, though intensified glucose control is recommended during pregnancy.

What should I know about interactions with other medicines?

The official regulatory profile for Actrapid Penfill (Human Insulin) is defined by pharmacodynamic interactions with other substances, which shift blood glucose control. Regulatory documents do not state any specific contraindicated combinations or pharmacokinetic interactions involving CYP enzymes or drug transporters.

Pharmacodynamic Interactions

Interaction Effect	Examples of Documented Substances
Increase in Hypoglycemia Risk (May Reduce Insulin Requirement)	Oral anti-diabetic medicinal products, ACE Inhibitors, Beta-blockers, MAO Inhibitors, Salicylates, Anabolic Steroids, Sulfonamides.
Increase in Hyperglycemia Risk (May Increase Insulin Requirement)	Corticosteroids, Oral Contraceptives, Thiazide diuretics, Thyroid Hormones, Sympathomimetics, Growth Hormone, Danazol.

Interaction-Context Constraints

The co-administration of alcohol is officially documented as potentially intensifying or reducing the glucose-lowering effect of insulin. Beta-blockers are specifically noted in regulatory labels to mask some of the typical symptomatic warning signs of hypoglycemia. Furthermore, official warnings exist regarding the co-administration of human insulin with Pioglitazone (thiazolidinedione class); patients should be observed for signs and symptoms of cardiac failure if this combination is used.

Mechanism of Action

Actrapid Penfill is a fast-acting preparation of human insulin, which functions as an exogenous ligand for the insulin receptor. Its mechanism involves a series of cellular and molecular events to modulate key processes of energy metabolism.

Receptor-Mediated Cellular Engagement

Its active substance binds to insulin receptors (IR) on target cells, particularly in muscle, fat, and liver tissue. This binding activates the receptor's intrinsic tyrosine kinase activity, initiating the complex intracellular signaling cascade that modulates downstream signaling pathways influencing glucose and lipid homeostasis.

Modulation of Glucose Transport and Metabolism

The activation cascade engages the PI3K/Akt pathway, leading to the translocation of GLUT4 transporter proteins to the cell surface, thus increasing cellular uptake of glucose. Concurrently, it promotes glucose storage by increasing glycogen synthesis while suppressing endogenous glucose production (gluconeogenesis and glycogenolysis), resulting in decreased concentration of glucose in the extracellular fluid.

Regulation of Anabolic and Catabolic Processes

The mechanism regulates overall metabolic balance by stimulating anabolism (protein and lipid synthesis) and inhibiting catabolism. This occurs by decreasing the mobilization of free fatty acids (lipolysis) and reducing the breakdown of protein (proteolysis), thereby promoting an anabolic state favoring substrate storage within targeted metabolic pathways.

Dosage and Administration Information

Actrapid Penfill is used according to specific instructions and standard protocols to ensure proper insulin delivery and efficacy.

Administration Scope

Feature	Guideline Details
Route of administration	The Penfill cartridge is intended for subcutaneous (SC) injection using a compatible delivery pen system. Use of the active ingredient intravenously (IV) or intramuscularly (IM) is restricted to specialized clinical settings and is typically administered by a healthcare professional.
Dosing schedule	The required dosage is highly individualized based on metabolic needs. A common maintenance range for total daily insulin requirement is typically 0.5 to 1.0 IU per kg of body weight. All doses require continuous titration based on blood glucose monitoring.
Timing in relation to meals	As a short-acting product, it must be administered subcutaneously 30 minutes before a meal or carbohydrate-containing snack to synchronize with post-meal glucose absorption.
Preparation requirements	The solution must be clear and colorless before use. It must be visually inspected, and if it appears cloudy or contains any solid particles, it should not be used.
Age-group administration rules	Patients with renal or hepatic impairment may require a dose reduction due to decreased insulin clearance. Increased monitoring and potential dose adjustment are also necessary for older adults (ge 65 years).
Special procedural conditions	Injection sites must be rotated continuously within the same anatomical region (e.g., abdomen, thigh). The needle must remain in the skin for at least six seconds following injection to confirm full dose delivery. The Penfill cartridge is not recommended for use in insulin pumps (CSII).

Connection to the Overall Use Protocol

The established instructions structure the use of Actrapid Penfill as a scheduled, meal-dependent injection protocol. This defines an individualized dosage within a standard range, requiring precise timing (30 minutes pre-meal) and specific administration techniques like site rotation and device constraints (SC use only).

Recent Clinical Evidence

Actrapid Penfill: Recent Clinical Evidence

Actrapid Penfill contains Human Insulin (rDNA), a neutral, short-acting insulin. Clinical evidence supporting its use in the management of diabetes mellitus spans decades, confirming its role in controlling blood glucose levels in both Type 1 and Type 2 diabetes.

Efficacy and Glycemic Control

Studies comparing Human Insulin (Actrapid) with other insulin products, such as older purified porcine insulin, found that the therapeutic effect on mean blood glucose levels and glycosylated hemoglobin (HbA1c) was comparable. For instance, double-blind trials demonstrated that Human Insulin achieved near-normoglycemia similar to its porcine counterparts. The primary benefit observed with all short-acting insulins, including Actrapid, is their rapid onset, typically starting to lower blood glucose within 30 minutes of injection, with a total duration of action lasting approximately 8 hours.

Use in Special Populations

Actrapid can be utilized across a wide patient demographic, including children and adolescents, and its use during pregnancy is permitted as insulin does not cross the placental barrier. Studies advise that blood glucose control should be intensified and monitored closely during pregnancy, as insulin requirements are known to fluctuate.

Research has also specifically addressed use in patients with renal (kidney) or hepatic (liver) impairment. These conditions may reduce an individual's insulin requirements, making intensified blood glucose monitoring necessary to adjust the dosage accordingly.

Comparator Trials

Later-generation, ultra-rapid-acting insulin analogs (like insulin aspart) have been the subject of comparative trials with regular human insulin (Actrapid). These studies often evaluate differences in postprandial (after-meal) glucose excursions and the incidence of hypoglycemia (low blood sugar), which is the most common side effect reported across all insulin therapies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Actrapid Penfill (FAQ)

Q: Is Actrapid Penfill the same as other insulins?

A: Actrapid Penfill is classified as a short-acting human insulin product. According to official product information, its action profile is distinct from other types of insulin, such as intermediate-acting or long-acting preparations. Its action profile typically shows onset within 30 minutes and a duration of action of approximately 8 hours.

Q: What is the difference between Actrapid and Actrapid Penfill?

A: The name difference refers to the packaging and delivery method. Actrapid is the brand name for the human insulin solution. Penfill refers specifically to the 3 mL cartridge presentation, which is designed for use in a compatible insulin pen device. Actrapid is also available in a traditional vial format designed for use with a syringe or for clinical administration.

Q: Does Actrapid Penfill interact with common over-the-counter medications?

A: Regulatory documents indicate that Actrapid Penfill can interact with various substances, including some found in non-prescription medicines. For example, substances known as salicylates (which include aspirin) may intensify the glucose-lowering effect of insulin. This interaction may increase the glucose-lowering effect, which is associated with the risk of hypoglycaemia.

Q: Why does Actrapid Penfill come in a Penfill cartridge?

A: The Penfill cartridge is a specific type of container designed to work with compatible insulin delivery pen systems. The design provides a convenient, multi-dose system compatible with specific insulin pen devices. Official information describes the usage associated with these pre-filled systems.

Q: Do studies support the long-term use of Actrapid Penfill?

A: The active ingredient in Actrapid Penfill is human insulin, and the clinical evidence supporting its use in managing chronic diabetes mellitus spans decades. The historical evidence supports its recognized role in the long-term management of diabetes mellitus.

Q: Can Actrapid Penfill cause headaches or dizziness?

A: According to official safety information, headaches and dizziness are commonly reported symptoms that can be associated with the use of insulin. These feelings are recognized signs associated with hypoglycaemia (low blood sugar), which is the most frequent adverse reaction to insulin therapy.

Q: What happens if Actrapid Penfill is exposed to extreme temperatures?

A: Actrapid Penfill is sensitive to temperature extremes. If the cartridge has been frozen or exposed to temperatures above the recommended limits, the insulin within the cartridge may break down. This chemical change can make the medicine less effective, and official instructions indicate the product should be discarded if it has been improperly stored.

Q: What do patients commonly misunderstand about using a Penfill device?

A: Patient usage information emphasizes that failing to remove the needle after each injection may result in insulin leakage or air entering the cartridge. Additionally, official procedural guidelines require continuous injection site rotation within the recommended regions to prevent tissue changes.

Q: What is the typical shelf life of an unopened Actrapid Penfill cartridge?

A: The official shelf life for an unopened Actrapid Penfill cartridge is typically 30 months (two and a half years) from the date it was manufactured. This duration assumes the cartridge is stored correctly in the refrigerator, protected from light, and has not been exposed to freezing temperatures.

Q: What is the main benefit of Actrapid Penfill over older insulin formats?

A: One key aspect is that Actrapid Penfill contains biosynthetic human insulin, which is manufactured to provide a high standard of purity and consistent action compared to older animal-sourced insulins. The Penfill cartridge design provides a multi-dose delivery system for use with an insulin pen.

Q: Can Actrapid Penfill be mixed with other types of insulin?

A: According to regulatory guidance, regular human insulin (which Actrapid contains) can be mixed with NPH (intermediate-acting) insulin if using a syringe. However, the Penfill cartridge is specifically designed as a closed, stand-alone product and is not intended for manual mixing or refilling.

Q: Can Actrapid Penfill cause weight changes?

A: Official regulatory documents list weight gain as a potential side effect associated with the use of Actrapid. Patients are advised to discuss any unexpected weight changes with their healthcare provider during treatment.

Q: What happens if I miss a dose of Actrapid Penfill?

A: If a dose is forgotten, regulatory patient information advises against taking a double dose to compensate. Patient information suggests immediately testing blood sugar level. Due to the individual nature of insulin regimens, patients should seek guidance from a healthcare provider for specific instructions on managing a missed dose.

Q: What are the possible signs of low blood sugar from Actrapid Penfill?

A: Low blood sugar, known as hypoglycaemia, is a very common side effect of insulin and is associated with several physical signs. These signs may include sweating, trembling, anxiety, a fast heartbeat (palpitations), dizziness, blurred vision, or tingling lips.

Q: Can Actrapid Penfill affect my vision?

A: Official safety information indicates that vision changes may be observed, particularly as a temporary effect when initiating insulin treatment. Additionally, blurred vision is a common sign of low blood sugar. Regulatory documents also note that worsening of diabetic retinopathy is a rare potential side effect.

Q: Are there different strengths or concentrations of Actrapid Penfill?

A: According to the official regulatory composition information, the Actrapid Penfill cartridge is manufactured and supplied in only one concentration. This standardized concentration is 100 IU/ml (international units per milliliter).

Q: How does stress or illness affect the use of Actrapid Penfill?

A: Official warnings note that physiological states such as illness or stress can cause changes in blood sugar levels, often leading to a temporary need for a higher insulin dose (hyperglycaemia). Regulatory guidance indicates the need for intensified blood glucose monitoring during these episodes.

Q: Is it normal to feel hungry after using Actrapid Penfill?

A: Yes, a feeling of increased hunger is one of the recognized symptoms that may signal the onset of hypoglycaemia (low blood sugar). Since low blood sugar is the most common adverse reaction associated with insulin use, this feeling is a documented signal that the body may need glucose.

Q: Is there any information on Actrapid Penfill's impact on driving ability?

A: Regulatory documents contain specific warnings regarding the ability to drive or operate machinery. The ability to concentrate and react may be impaired as a result of hypoglycaemia (low blood sugar), which constitutes a risk. Patients using insulin should be made aware of the need to take precautions to prevent low blood sugar episodes while driving.

How should Actrapid Penfill be stored and disposed of?

Official Storage and Disposal Requirements

Storage of Actrapid Penfill is strictly regulated based on whether the cartridge is in use or unopened. Unopened cartridges must be stored in a refrigerator between 2 C and 8 C and kept out of the sight and reach of children. The product must never be frozen.

Condition	Temperature and Duration
Unopened (Not in Use)	Store refrigerated (2 C to 8 C) until expiry date.
In Use (Opened or Spare)	Store below 25 C (or 30 C) for a maximum of 6 weeks (42 days).

All cartridges must be protected from light by remaining in the original outer carton. Do not refrigerate a cartridge once it is in use. Needles must be discarded after each injection, and used or expired cartridges must be disposed of in accordance with local regulations for sharps and pharmaceutical waste.

Actrapid Penfill